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S U M M A R Y
Objective: Gastroenteritis caused by a single pathogen or multiple pathogens remains a major diagnostic
challenge for the laboratory. The treatment of diarrhoea is based on microbiological results. Diagnosis is
achieved using different laboratory techniques that have variable sensitivity and speciﬁcity. xTAG GPP is
a new multiplex PCR assay that simultaneously detects 15 different pathogens responsible for diarrhoea.
The results of the ﬁrst multicentre study in Italy to evaluate the potential clinical application of the GPP
assay in the laboratory diagnosis of diarrhoea are reported here.
Methods: Faeces specimens (N = 664) from hospitalized patients were tested with the GPP assay using a
Luminex 200 instrument. All specimens were run using comparator methods following a routine
algorithm: culture for bacteria, enzyme immunoassay and PCR for viruses, and microscopy for parasites.
Results: Of the samples tested with the GPP, 53.61% (356/664) gave positive results, as compared to
45.33% by routine testing. Of the positive specimens, 34.55% showed the presence of genomic DNA from
multiple pathogens. The Luminex method showed an increase in the percentage of positivity of 8.28%.
Conclusions: The GPP assay can be considered a helpful tool for the detection of gastrointestinal
pathogens, with a hands-on time of 5 h; it provides accurate data for the clinical management of
hospitalized patients and for epidemiological surveillance.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Infectious gastroenteritis (GE) is a signiﬁcant cause of morbidity
and mortality worldwide. Diarrhoea, the main clinical symptom of
GE, is currently the second leading cause of illness worldwide after
the common cold.1 In 2009, the World Health Organization (WHO)
estimated 2 billion cases of severe illness related to GE, with about
1.8 million deaths per year.2* Corresponding author. Tel.: +39 051 2144316; fax: +39 051 2143076.
E-mail address: cate.vocale@gmail.com (C. Vocale).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).The microbiological aetiology of GE may include bacterial, viral,
or parasitic pathogens, and the related clinical picture can range
from mild to severe and life-threatening cases.3 The ability to
manage severe GE cases in the fastest and best possible way is
largely dependent on the prevention of and control measures for
the spread of infectious diarrhoeal diseases.
The effective treatment of GE is dependent upon an efﬁcient
and rapid diagnostic algorithm that allows the implementation of
drug therapy and/or isolation measures to prevent the spread of
the infectious agent from the ill patient to healthy individuals. The
laboratory diagnosis of GE is currently based on the combined use
of different tests, each one with variable sensitivity and speciﬁcityciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
C. Vocale et al. / International Journal of Infectious Diseases 34 (2015) 33–3734and typically able to identify only a deﬁned number of pathogens
at a time.4–6
Most clinical microbiology laboratories use conventional
diagnostic methods, such as culture, microscopy, and ELISA, to
identify GE-related pathogens.7 This approach involves multiple
selective media and reagents, followed by the identiﬁcation of the
microorganism and biochemical testing. When microscopy is used,
the correct identiﬁcation of ova and parasites depends largely upon
the experience and skill of the microscopist. ELISA offers generally
stable and quality-controlled kits, but typically this technique has
long run times,8 and the overall performance depends on the
quality of capture and detection of antibodies.9With culture-based
protocols, the ﬁnal results are usually obtained at 3–4 days and the
sensitivity may be affected by the limited viability of selected
microorganisms during sampling and transportation of the
specimen. Taken together, all of the above reported weaknesses
in the diagnostic workﬂow may lead to empiric and often
inappropriate and delayed therapy of GE.
Molecular-based methods could streamline the laboratory
workﬂow, improve the diagnostic performance, and consequently
enhance clinical management, given the better and more rapid
identiﬁcation of the aetiology of GE cases.10 A few commercial tests
are now available with CE-IVD marking for the detection of enteric
pathogens in human stool. In particular, the Luminex xMAP
Technology offers a novel platform for high-throughput nucleic
acid detection and can be used in a variety of applications.1
Recently, the use of this technology has enabled the sensitive and
speciﬁc detection of the major gastrointestinal pathogens.11
xTAG GPP (GPP), manufactured by Luminex Corporation
(Austin, TX, USA), is a new qualitative bead-based multiplex assay
able to simultaneously detect, in a single human stool sample,
15 different pathogens, including those responsible for hospital-
acquired infections such as Clostridium difﬁcile, food-borne illness
agents like Salmonella, and viral paediatric diarrhoea pathogens
such as a rotavirus.
The aim of this study was to compare the analytical
performance of the GPP assay with the routine tests used for
the detection of GE-related pathogens in a population of patients
suffering from suspected GE. In addition, the potential clinical
application of this multiplex assay in the diagnostic practice and
management of diarrhoea was also evaluated.
2. Materials and methods
A total of 664 stool samples were collected between January 1,
2011 and March 31, 2013 from hospitalized symptomatic patients
suffering from suspected GE. One sample was received from each
patient. All raw stool specimens and stool specimens in Cary–Blair
transport medium (Faecal swab; Copan, Brescia, Italy) were
collected and submitted for microbiological evaluation at the
following four laboratories: St. Orsola Malpighi University Hospital
(Bologna), ‘‘L. Sacco’’ University Hospital (Milan), Ospedale Maggiore
Policlinico (Milan), and the Unit of Microbiology of the Hub
Laboratory of the Greater Romagna Area (Pievesestina). All of the
specimens were ﬁrst evaluated using the available routine methodsTable 1
Routine methods for the diagnosis of gastroenteritis
Routine Tests for 
Stool culture Single or few bacterial pathogens per test (i.e., Shigella,
Campylobacter, Salmonella)
Parasites Parasitic pathogens 
ELISA Viral pathogens and Clostridium difﬁcile infection (GDH) 
Rapid tests Viral pathogens and C. difﬁcile infection (toxin A/B) 
Real-time PCR Viral pathogens 
GDH, glutamate dehydrogenas.at each individual participating laboratory, as summarized in
Table 1.
The stool samples were tested with the GPP test after the
routine assays had been performed, using the Luminex 200 instru-
ment; testing was performed in accordance with the manufac-
turer’s instructions. Brieﬂy, the samples were pre-treated as
described in the package insert and then underwent automated
nucleic acid extraction using the NucliSENS EasyMAG system
(BioMe´rieux, Marcy l’Etoile, France). The GPP assay includes an
RNA-based internal control (MS2 bacteriophage), which was
spiked into each sample prior to extraction, to control for PCR
inhibition and assess each step in the workﬂow and consequently
monitor the entire assay performance.
The RT-PCR reactions and subsequent hybridization step were
performed according to the instructions in the GPP manual, by a
single trained operator who was blinded to the identity of the
specimens and to the results obtained with the standard diagnostic
methods. PCR ampliﬁcation was performed using a Mastercycler
gradient thermal cycler (Eppendorf, Hamburg, Germany) using the
recommended cycling parameters; negative and positive controls
were included in all runs of the GPP assay.
The data were acquired on the Luminex 200 analyzer and data
analysis was carried out using TDAS data analysis software.
All clinical specimens were also tested according to the
following routine algorithm: conventional culture for the detection
of bacteria,12 enzyme immunoassay (EIA) for C. difﬁcile detection
(Wampole C Diff Quik Chek EIA (GDH-Q) and Wampole Tox A/B
Quik Chek EIA (AB-Q); Alere S.r.l., Italy), Rapid Strip ROTA/ADENO
(Meridian Bioscience Inc., Italy) or real-time PCR for virus
detection,13 and microscopic examination for parasite identiﬁca-
tion (Lugol, Giemsa) (Table 1).14
3. Results
A total of 301/664 (45.33%) samples tested positive with the
routine tests versus 356/664 (53.61%) using the GPP assay
(Figure 1). In the majority of the positive samples, only one target
was detected by routine workﬂow, whereas 123/356 (34.55%) of
the GPP-positive specimens were positive for multiple targets
(Figure 2). This suggests the presence of genomic sequences from
different pathogens simultaneously; these results clearly open the
hypothesis of co-infecting germs in one individual sample
(Table 2). In particular, with the routine diagnostic procedure,
adenovirus, norovirus, and rotavirus were the most frequently co-
detected putative pathogens, whereas with the Luminex method,
the main co-infections detected were due to C. difﬁcile, norovirus,
and Cryptosporidium.
In relation to the bacterial panel, the routine tests were not able
to identify all of the double infections, unlike the Luminex method,
which in 9/74 positive cases for Salmonella showed the
simultaneous presence of the genome of this organism together
with another pathogenic microorganism (Table 2).
In most cases, the additional target detected was not the one
hypothesized by the clinician.Method Turn-around time




Detection of a single antigen per test 72 h
Detection of a single virulence factor/toxin per test 72 h
Ampliﬁcation of a speciﬁc DNA fragment 24 h
Figure 1. Comparative results between routine tests and Luminex method.
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multiple positive results. The real clinical relevance of the presence
of this DNA remains to be clariﬁed, since pathogens such as
Salmonella and Giardia may be present in humans as colonizing
organisms. The results obtained were comparable across all the
centres involved in the study. The percentage of positive samples
detected with the Luminex method was superior by 8.28% in
respect to the positives found by the standard diagnostic methods
(53.61% and 45.33%, respectively).Figure 2. Summary of xTAG GPP positive sample4. Discussion
This study showed that the xTAG GPP has very good sensitivity
and speciﬁcity for the detection of a large panel of pathogens
related to acute diarrhoea, with the capability of increased
detection and improved diagnostic yields from stool specimens
as compared to the reference methods used routinely. An added
value of this new molecular test is the capability of identifying the
presence of pathogens that would remain undetected under thes compared with panel of routine positivity.
Table 2





Co-infection Other pathogens detected (number)
Bacterial targets
Clostridium difﬁcile 58 36 22 Norovirus (7), Shigella (1), adenovirus (1), rotavirus (5), Giardia (1),
Cryptosporidium (1), Campylobacter (1), norovirus/adenovirus (2), norovirus/
rotavirus (2), norovirus/Cryptosporidium (1)
Salmonella 74 65 9 Giardia (1), norovirus (4), adenovirus (1), Campylobacter (1), norovirus/
rotavirus (1), Cryptosporidium/Giardia (1)
Shigella 11 7 4 Giardia (2), C. difﬁcile (1), norovirus (1)
Campylobacter 29 23 6 Norovirus (2), adenovirus (2), C. difﬁcile (1), rotavirus/Cryptosporidium (1)
STEC 7 4 3 Norovirus (1), E. coli O157 (1), adenovirus (1)
ETEC 4 3 1 Norovirus (1)
Viral targets
Adenovirus 18 11 7 Campylobacter (2), C. difﬁcile (1), Salmonella (1), rotavirus/STEC (2)
Norovirus 86 43 43 C. difﬁcile (8), Giardia (2), Campylobacter (3), Salmonella (4), ETEC (1), rotavirus
(9), Cryptosporidium (4), Shigella (1), adenovirus (2), rotavirus/Salmonella (1),
C. difﬁcile/adenovirus (2), C. difﬁcile/Cryptosporidium (1), rotavirus/
Cryptosporidium (1), rotavirus/C. difﬁcile (2), ETEC/Cryptosporidium (1),
Cryptosporidium/E. histolytica (1)
Rotavirus 86 77 9 C. difﬁcile (5), E. coli O157 (1), Cryptosporidium (2), Campylobacter/
Cryptosporidium (1)
Parasitic targets
Giardia 14 8 6 Norovirus (2), Shigella (2), Salmonella (1), Cryptosporidium/Salmonella (1)
Entamoeba histolytica 1 0 1 Norovirus/Cryptosporidium (1)
Cryptosporidium 17 5 12 Norovirus (3), rotavirus (2), C. difﬁcile (1), norovirus/C. difﬁcile (1), norovirus/
rotavirus (1), Campylobacter/rotavirus (1), norovirus/ETEC (1), Giardia/
Salmonella (1), norovirus/E. histolytica (1)
STEC, shiga toxin-producing Escherichia coli; ETEC, enterotoxigenic Escherichia coli.
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pathogens, even if only by genome detection, that were not among
those hypothesized by the treating physician. This is clearly a
consequence of the fact that the standard diagnostic procedures
are technically based on performing individual tests focused on the
most probable pathogens as suggested by patient presentation and
as ordered by the physician.
The multiplex molecular-based approach, such as the GPP, is
not speciﬁcally oriented towards a single microbe, but can
simultaneously detect the presence of all of the target analytes
included in the panel. Based on this broad range capability to
detect multiple genomic targets and the enhanced sensitivity that
characterizes diagnostic methods based on nucleic acid ampliﬁca-
tion, the GPP appears to be a promising tool for the detection and
identiﬁcation of GE-related pathogens. It is able to replace a
heterogeneous set of methods commonly seen in laboratories, such
as culture, ELISA, and rapid tests, with a single standard assay,
above all for undetected pathogens. In addition, as evidenced in
this study, the assay provides an improved workﬂow with a hands-
on time of no more than 5 h.
A point for discussion is that molecular-based methods only
detect the presence of genomic sequences derived from both living
and dead putative pathogens. Thus, the clinical relevance of
detecting pathogen-derived DNA in a microbiologically compli-
cated specimen such as stool, and where all the genes derived from
the intestinal microbiome could be present, must be considered.
Today, the aetiology of acute infectious diarrhoea is generally
accepted as monomicrobial, meaning that one pathogen is
accepted as responsible for the particular disease episode. The
results obtained in this study clearly demonstrate that multiple
diarrhoeal pathogens are frequently present simultaneously in the
stool of patients suffering from acute GE, and their nucleic acids
can be detected and identiﬁed using a comprehensive multiplex
molecular test, such as the GPP. Further, this suggests the
possibility that multiple organisms can contribute to the
pathogenesis of this illness.
This hypothesis may also be corroborated by the newly
accepted concept of the human microbiome as an enormousmicrobial community that includes viruses, bacteria, fungi, and
likely protozoa.15 This large community of diverse microorganisms
must be regarded as an additional ‘organ’ that largely contributes
to the maintenance of the body homeostasis and the health of each
individual. Based on this fact and on the ﬁndings of this study,
demonstrating the presence of multiple pathogens in the stool of
acute GE patients, the hypothesis of diarrhoea as a ‘dysmicrobial
syndrome’ clearly arises. In other words, diarrhoea could be seen as
a condition of altered ecological equilibrium among the members
of the human gut microbiome. A test like the xTAG GPP that can
identify multiple organisms within one specimen could be helpful
to determine a more precise aetiology of acute GE, without the
need to test the sample several times with different panels
(bacterial, viral, and parasitological), reducing, although only
24 samples/day, all the work in the hands of a single operator.
This expanded detection capability is particularly relevant in
light of the latest knowledge about the human gut microbiome,
whose composition is greatly inﬂuenced by several host-associated
parameters (antibiotic therapy, nutrition and food consumption,
genetic background, etc.), and emphasizes the role of this huge
microbial community in the development of enteric diseases.16–19
The use of multiplex ampliﬁed molecular techniques in the ﬁeld of
GE diagnosis could provide additional evidence to the above
hypothesis.20 Although the detection of a nucleic acid sequence
does not imply the presence of a viable organism, additional
investigations are warranted in order to clarify the putative role of
mixed infections in the genesis of acute GE. Detection does not
necessarily mean disease, as many pathogens can exist asymptom-
atically (e.g., Salmonella spp) or subclinically (e.g., C. difﬁcile non-
toxigenic strains) in a colonization-like status.21,22
Furthermore, great emphasis should be given to the manage-
ment of ‘true-negatives’ resulting from the molecular test, where
negativity is truly associated with the absence of the putative
pathogenic organism in the sample tested and not due to a
limitation of the diagnostic test used, especially considering the
improved sensitivity of xTAG GPP.
The most attractive feature of multiplex diagnostic methods for
the clinician lies in the wide spectrum of pathogens identiﬁed and
C. Vocale et al. / International Journal of Infectious Diseases 34 (2015) 33–37 37the rapidity of results. There are still many interpretative points
that must be considered, including an in-depth analysis and
clinical correlation of the results, and the overall cost–beneﬁt ratio
should be determined before introducing this approach into the
routine laboratory workﬂow for GE. Of course a general increase in
laboratory costs would be expected, since a molecular-based
technique implies a higher cost than standard methods in terms of
reagents and personnel training. On the other hand, the introduc-
tion of a sensitive molecular method has been shown in this study
to greatly increase the overall performance of the laboratory
diagnosis of GE, thus likely allowing a better management of the
patient both in terms of a reduction in hospitalization time and the
appropriate choice of therapy, thereby reducing overall costs.
Moreover, as shown in this study, the GPP allowed us to identify
undiagnosed infections as well as unsuspected co-infections. One
last aspect of the ﬁndings of this study that should be highlighted is
that the use of the GPP allowed a substantial reduction in the
personnel involved in the workﬂow of GE diagnosis. Having
performed this study, we emphasize the great promise that this
novel molecular approach gives to solving cases of unknown
aetiology; it is important to note that the sensitivity is signiﬁcant
not only in those symptomatic cases where the laboratory data
conﬁrm the clinical picture, but especially in those cases where the
diagnostic suspicion is very strong, but symptoms are unclear.
In conclusion, in this study, the xTAG GPP assay was found to
have great potential for improving the diagnosis of GE. Additional
larger studies are necessary to further investigate and conﬁrm this
possibility.
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